Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02293837

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:30.641926+00:00

Published At

2021-08-17T00:00:00+00:00

Record Updated At

2021-09-08

Results Posted At

2021-08-17

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Type 1 Diabetes Mellitus", "New-onset Type 1 Diabetes Mellitus", "T1DM", "T1D"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2021-09-08"

protocolSection.identificationModule.nctId

"NCT02293837"

protocolSection.identificationModule.officialTitle

"Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2021-08-17"

Study condition terms

• Type 1 Diabetes Mellitus (protocolSection.conditionsModule.conditions)
• New-onset Type 1 Diabetes Mellitus (protocolSection.conditionsModule.conditions)
• T1DM (protocolSection.conditionsModule.conditions)
• T1D (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.